ArticleNanoscale2019
Ultrabright fluorescent silica nanoparticles for in vivo targeting of xenografted human tumors and cancer cells in zebrafish.
Article in Nanoscale, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 25 citations in OpenAlex.
- Long-Term Cell-Membrane-Coated Ultrabright Nanospheres for Targeted Cancer Cell Imaging and Hydrophobic Drug Delivery.Chemistry of materials : a publication of the American Chemical Society · 2025Article
- Concerning influences of micro/nano plastics on female reproductive health: focusing on cellular and molecular pathways from animal models to human studies.Reproductive biology and endocrinology : RB&E · 2024Review
- Ultrabright fluorescent particlesNanoscale · 2024Review
- Toxicity evaluation of silica nanoparticles for delivery applications.Drug delivery and translational research · 2023Review
- Towards the Use of Individual Fluorescent Nanoparticles as Ratiometric Sensors: Spectral Robustness of Ultrabright Nanoporous Silica Nanoparticles.Sensors (Basel, Switzerland) · 2023Article
- Zebrafish Models for the Safety and Therapeutic Testing of Nanoparticles with a Focus on Macrophages.Nanomaterials (Basel, Switzerland) · 2021Review
- Zebrafish as a Model for Anticancer Nanomedicine Studies.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Ultrabright Fluorescent Silica Nanoparticles for Dual pH and Temperature Measurements.Nanomaterials (Basel, Switzerland) · 2021Article
- Functionalized Fluorescent Silica Nanoparticles for Bioimaging of Cancer Cells.Sensors (Basel, Switzerland) · 2020Article
- In Vivo Targeting of Xenografted Human Cancer Cells with Functionalized Fluorescent Silica Nanoparticles in Zebrafish.Journal of visualized experiments : JoVE · 2020Article
- Ultrabright Fluorescent Silica Nanoparticles for Multiplexed Detection.Nanomaterials (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
New ultrabright fluorescent silica nanoparticles capable of the fast targeting of epithelial tumors in vivo are presented. The as-synthesized folate-functionalized ultrabright particles of 30-40 nm are 230 times brighter than quantum dots (QD450) and 50% brighter than the polymer dots with similar spectra (excitation 365 nm and emission 486 nm). To decrease non-specific targeting, particles are coated with polyethylene glycol (PEG). We demonstrate the in vivo targeting of xenographic human cervical epithelial tumors (HeLa cells) using zebrafish as a model system. The particles target tumors (and probably even individual HeLa cells) as small as 10-20 microns within 20-30 minutes after blood injection. To demonstrate the advantages of ultrabrightness, we repeated the experiments with similar but 200× less bright particles. Compared to those, ultrabright particles showed ∼3× faster tumor detection and ∼2× higher relative fluorescent contrast of tumors/cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.